查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1511921

美國生物防禦市場規模、佔有率和趨勢分析報告：按產品和細分市場預測，2024-2030 年

U.S. Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國生物防禦市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國生物防禦市場預計將達到179億美元，2024年至2030年複合年成長率為4.1%。

美國生物防禦市場受到政府資金增加、全球健康問題、技術進步、監管要求、合作和準備需求以及經濟獎勵等因素的推動。這些因素確保提供有效的生物防禦解決方案，保護人們免受潛在的生物威脅，並為產業的成長和發展做出貢獻。美國生物防禦市場受益於基因組學、生物資訊學和合成生物學等技術的快速進步。這些創新能夠快速識別病原體、開發標靶治療並改善診斷。

2022 年 9 月，國防部 (DoD) 計劃投資 10 億美元加強國內生物工業製造基礎設施，讓美國創新者更容​​易獲得這些基礎設施，特別是在商業和國防供應方面，旨在刺激私營和公共部門擴張。此外，國防部將額外撥款2億美元，用於加強這些設施的生物安全和網路安全措施。同時，美國農業部 (USDA) 承諾撥款 5 億美元，利用生物技術和生物製造領域的進步來津貼美國農民，促進獨立、創新和永續的美國化肥生產。推出。

美國生物防禦市場報告亮點

  • 由於其高致死率、易於製造、穩定性、大規模殺滅潛力以及持續改進現有治療方法和疫苗的需要，到 2023 年，炭疽菌將佔產品佔有率的 28.1%。
  • 預計輻射/核武產業在預測期內將以顯著的複合年成長率成長。
  • 生物恐怖主義感染疾病的增加以及新出現的感染疾病的可能性正在促進美國生物防禦市場的成長。
  • 2022 年 1 月，Integrated Viral Protection LLC (IVP) 推出了一款可攜式空氣過濾設備，可以一次清除多種空氣傳播的病毒，包括 COVID-19 和炭疽菌孢子。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國生物防禦市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國生物防禦市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國生物防禦市場：產品估算與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 美國生物防禦市場展望：依產品分類
  • 2018-2030年市場規模、預測及趨勢分析

第5章競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • XOMA Corporation
    • Altimmune, Inc.
    • EMERGENT
    • Dynavax Technologies
    • SIGA Technologies
    • Elusys Therapeutics, Inc.
    • Ichor Medical Systems
    • Dynport Vaccine Company（General Dynamics Information Technology, Inc.）
    • Cleveland Biolabs
    • Bavarian Nordic
    • Ology Bioservices, Inc.
    • Alnylam Pharmaceuticals, Inc.
Product Code: GVR-4-68040-313-4

U.S. Biodefense Market Growth & Trends:

The U.S. biodefense market is anticipated to reach USD 17.90 billion by 2030, and is expected to grow at a CAGR of 4.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The U.S. biodefense market is driven by factors such as increased government funding, global health concerns, technological advancements, regulatory requirements, the need for collaboration and preparedness, and economic incentives. These drivers contribute to the growth and development of the industry, ensuring that effective biodefense solutions are available to protect populations from potential biological threats. The U.S. biodefense market benefits from rapid advancements in technology, such as genomics, bioinformatics, and synthetic biology. These innovations enable faster identification of pathogens, development of targeted therapies, and improved diagnostics.

In September 2022, the Department of Defense (DoD) planned to invest USD 1 billion to boost domestic bio-industrial manufacturing infrastructure, facilitating accessibility for U.S. innovators, which aimed at incentivizing private and public sectors to expand manufacturing capacities, particularly for critical chemicals vital to commercial and defense supply chains. In addition, the DoD was expected to allocate an extra USD 200 million to enhance biosecurity and cybersecurity measures for these facilities. Collectively, the U.S. Department of Agriculture (USDA) was expected to introduce a USD 500 million grant program in summer 2022 to foster independent, innovative, and sustainable American fertilizer production, leveraging advancements in biotechnology and biomanufacturing to support domestic farmers.

U.S. Biodefense Market Report Highlights:

  • Anthrax dominated the product segment with 28.1% share in 2023 owing to its high lethality, ease of production, stability, potential for mass casualties, and the ongoing need to improve existing treatments and vaccines.
  • The radiation/nuclear segment is expected to grow at a significant CAGR over the forecast period.
  • The increasing incidents of bioterrorism, the potential for new and emerging infectious diseases are contributing to the growth of the U.S. biodefense market.
  • In January 2022, Integrated Viral Protection LLC (IVP) launched a portable air filtration device capable of eliminating a wide range of airborne viruses, including COVID-19 and anthrax spores, in a single pass, boasting exceptional efficacy with patented biodefense technology.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Biodefense Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Biodefense Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Biodefense Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Biodefense Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Anthrax
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Smallpox
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Botulism
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Radiation/nuclear
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company heat map analysis, 2023
  • 5.4. Company Profiles
    • 5.4.1. XOMA Corporation
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Altimmune, Inc.
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. EMERGENT
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Dynavax Technologies
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. SIGA Technologies
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Elusys Therapeutics, Inc.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Ichor Medical Systems
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Cleveland Biolabs
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Bavarian Nordic
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
    • 5.4.11. Ology Bioservices, Inc.
      • 5.4.11.1. Company overview
      • 5.4.11.2. Financial performance
      • 5.4.11.3. Product benchmarking
      • 5.4.11.4. Strategic initiatives
    • 5.4.12. Alnylam Pharmaceuticals, Inc.
      • 5.4.12.1. Company overview
      • 5.4.12.2. Financial performance
      • 5.4.12.3. Product benchmarking
      • 5.4.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. biodefense market, by product, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. biodefense market: market outlook
  • Fig. 9 Biodefense competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. biodefense market driver impact
  • Fig. 14 U.S. biodefense market restraint impact
  • Fig. 15 U.S. biodefense market: Product movement analysis
  • Fig. 16 U.S. biodefense market: Product outlook and key takeaways
  • Fig. 17 Anthrax market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 18 Smallpox estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 19 Botulism market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Radiation/nuclear estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Others estimates and forecasts, 2018 - 2030 (USD Billion)